Welcome to MichiganLifeScience.com
MichiganLifeScience.com is part of a specialized network of state based biotechnology, medical device,
and life science sites that includes more than 3,500 biotechnology, medical device, pharmaceutical companies,
non-profit research institutions, universities and supporting service sector companies across the U.S.
This network addresses the growing informational and service needs of companies, patients, educators and others in
their respective states while providing clients the opportunity to cost effectively
advertise their job openings, events, facility availability and other services at the state level,
regionally or nationwide. We welcome your comments, suggestions and requests for informational content and supporting
services.
More...
|
|
Learn About Michigan's BioHistory
Why is there a biotechnology industry in Michigan? Will the industry continue
to grow in Michigan? What do other states have? Each state has a unique story
that explains why a given industry has developed in a specific region and not in others.
Through Michigan BioHistory, you can learn about the scientists,
institutions, political leaders, and significant events that have shaped and are still shaping
the biotechnology, medical device and life science industries in the state of Michigan.
More MI BioHistory...
|
Local News...
Free News Release Posting & Archiving Service
- Spectrum announces sale of injectable generic drugs to Sagent Spectrum Pharmaceuticals announced that it has sold its abbreviated new drug applications for its injectable generic drugs, ondansetron, carboplatin, fludarabine, and mitoxantrone, to Sagent Pharmaceuticals.
Spectrum Pharmaceuticals, Inc. May 09, 2008
- Bayer and Regeneron start additional Phase 3 Study for VEGF Trap-Eye Bayer HealthCare and development partner Regeneron Pharmaceuticals announced that the first patient has been dosed in the new VIEW 2 trial, a second Phase 3 clinical study in a development program evaluating VEGF Trap-Eye for the treatment of the neovascular form of age-related macular degeneration.
Bayer May 08, 2008
- AstraZeneca submits sNDA for Seroquel XR for the treatment of generalised anxiety disorder AstraZeneca announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for SEROQUEL XR(TM) Extended-Release Tablets to seek approval for the treatment of generalised anxiety disorder, including maintenance of antianxiety effect.
AstraZeneca May 08, 2008
- Invitrogen and WARF sign license agreement for human embryonic stem cells Invitrogen and the Wisconsin Alumni Research Foundation, the private, non-profit patenting and licensing organization for the University of Wisconsin-Madison, announced that they have signed a license for human embryonic stem cell patents for the development of research tools.
Invitrogen Corporation May 08, 2008
- FDA approves Strattera(R) for maintenance of ADHD in children and adolescents Eli Lilly and Company announced that the United States Food and Drug Administration has approved Strattera(R) (atomoxetine HCI) for maintenance treatment of Attention-Deficit/Hyperactivity Disorder in children and adolescents.
Eli Lilly and Company May 08, 2008
More... | Submit News Release | National News
|